Progyny (PGNY) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $2.72B
- As of Nov 17, 2026
- P/E
- 29.85x
- Trailing twelve months
- P/B
- 6.56x
- Latest reported equity
- P/S
- 2.03x
- Trailing twelve months
- ROE
- 22.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $2.72B
- As of Nov 17, 2026
- P/E
- 29.85x
- Trailing twelve months
- P/B
- 6.56x
- Latest reported equity
- P/S
- 2.03x
- Trailing twelve months
- ROE
- 22.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
29.85x
P/B
6.56x
P/S
2.03x
Earnings and dividend metrics▾
Earnings
EPS
$1.23
Earnings per share
BPS
$5.59
Book value per share
ROE
22.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.23 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $5.59 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 22.0%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 8.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $313M+8.9%
$287M
Jul–Sep '24
$313M
Jul–Sep '25
$341M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 5, 2026.
- Earnings per share increased 113.3% from the same quarter a year earlier.
- Revenue increased 8.9% from the same quarter a year earlier.
- Operating income increased 59.1% from the same quarter a year earlier.
- Net income increased 85.7% from the same quarter a year earlier.
Filed Nov 5, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Clapp GeoffreyChief Product Officer · Nov 11, 2026Open-market sale774 shares · $28KAvg. price $36.4158,235 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 10, 2026Open-market sale236,630 shares · $8.5MAvg. price $35.8446
Show 4 price lots
- 120,213 shares × $35.6068$4.3M
- 64,921 shares × $36.2851$2.4M
- 33,437 shares × $35.6067$1.2M
- 18,059 shares × $36.2851$655K
- Schlanger David JExecutive Chairman · Nov 10, 2026Open-market sale35,392 shares · $1.3MAvg. price $35.3613238,462 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 10, 2026Option exercise185,134 shares · $168KAvg. price $0.91947,602 shares held after
- Schlanger David JExecutive Chairman · Nov 10, 2026Option exercise35,392 shares · $32KAvg. price $0.91273,854 shares held after
- Schlanger David JExecutive Chairman · Nov 9, 2026Open-market sale161,208 shares · $5.8MAvg. price $35.7263238,462 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 9, 2026Open-market sale161,308 shares · $5.8MAvg. price $35.7257
Show 2 price lots
- 126,204 shares × $35.7257$4.5M
- 35,104 shares × $35.7257$1.3M
- Schlanger David JExecutive Chairman · Nov 9, 2026Option exercise161,208 shares · $147KAvg. price $0.91399,670 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 9, 2026Option exercise126,204 shares · $115KAvg. price $0.91923,776 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 5, 2026Open-market sale11,939 shares · $419KAvg. price $35.1296
Show 2 price lots
- 8,539 shares × $35.0906$300K
- 3,400 shares × $35.2276$120K
- Schlanger David JExecutive Chairman · Nov 5, 2026Open-market sale3,400 shares · $120KAvg. price $35.2209238,462 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Nov 5, 2026Option exercise3,400 shares · $3KAvg. price $0.91809,511 shares held after
- Schlanger David JExecutive Chairman · Nov 5, 2026Option exercise3,400 shares · $3KAvg. price $0.91241,862 shares held after
- Livingston Mark S.CHIEF FINANCIAL OFFICER · Nov 4, 2026Open-market sale2,139 shares · $64KAvg. price $3070,314 shares held after
- Swartz AllisonEVP, GC · Nov 2, 2026Grant or award8,160 shares · $0Avg. price $083,976 shares held after
- Cummings Melissa BChief Operating Officer · Oct 14, 2026Open-market sale1,879 shares · $53KAvg. price $2866,496 shares held after
- Cummings Melissa BChief Operating Officer · Oct 14, 2026Shares withheld for taxes1,559 shares · $43KAvg. price $27.3968,375 shares held after
- Swartz AllisonEVP, GC · Sep 23, 2026Open-market sale3,903 shares · $102KAvg. price $26.175,816 shares held after
- Clapp GeoffreyChief Product Officer · Sep 17, 2026Shares withheld for taxes819 shares · $22KAvg. price $27.3859,009 shares held after
- GORDON KEVIN KDirector · Sep 10, 2026Open-market sale23,000 shares · $633KAvg. price $27.53116,792 shares held after
Show 2 price lots
- 11,500 shares × $27.9442$321K
- 11,500 shares × $27.1181$312K
- GORDON KEVIN KDirector · Sep 10, 2026Shares withheld for taxes21,000 shares · $572KAvg. price $27.2418,292 shares held after
Show 2 price lots
- 10,500 shares × $27.24$286K
- 10,500 shares × $27.24$286K
- GORDON KEVIN KDirector · Sep 10, 2026Option exercise44,000 shares · $572KAvg. price $1328,792 shares held after
Show 2 price lots
- 22,000 shares × $13$286K
- 22,000 shares × $13$286K
- Livingston Mark S.CHIEF FINANCIAL OFFICER · Sep 4, 2026Shares withheld for taxes479 shares · $13KAvg. price $26.6172,453 shares held after
- Swartz AllisonEVP, GC · Sep 4, 2026Shares withheld for taxes479 shares · $13KAvg. price $26.6179,719 shares held after
- Anevski PeterCHIEF EXECUTIVE OFFICER · Sep 3, 2026Shares withheld for taxes5,361 shares · $141KAvg. price $26.29806,111 shares held after
- Livingston Mark S.CHIEF FINANCIAL OFFICER · Sep 3, 2026Shares withheld for taxes1,532 shares · $40KAvg. price $26.2972,932 shares held after
- Swartz AllisonEVP, GC · Sep 3, 2026Shares withheld for taxes828 shares · $22KAvg. price $26.2980,198 shares held after
- Livingston Mark S.CHIEF FINANCIAL OFFICER · Sep 2, 2026Shares withheld for taxes224 shares · $6KAvg. price $25.6674,464 shares held after
- Swartz AllisonEVP, GC · Aug 28, 2026Shares withheld for taxes1,352 shares · $35KAvg. price $25.8681,026 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Progyny (PGNY) stock information
NASDAQ
Progyny (PGNY) is listed on NASDAQ. Its market capitalization is about $2.7B. On trailing-twelve-month earnings the P/E ratio is 29.85, and the P/B ratio is 6.56. Return on equity is 22%. These figures are computed in-house from official filings and are reference information only.
Progyny — frequently asked questions
- What is the P/E ratio of Progyny (PGNY)?
- On a trailing-twelve-month basis, PGNY trades at a P/E ratio of 29.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Progyny?
- PGNY has a market capitalization of about $2.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.